Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2016—The Clinical and Laboratory Standards Institute published a revised document titled “Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria (M45-Ed3).”
January 2016—Worthington Biochemical announced distribution rights to the Celase GMP compliant enzyme from Cytori Therapeutics. The Celase GMP product offering allows Worthington customers focused on cell isolation studies to facilitate a smooth transition from bench and animal research to downstream clinical applications.
January 2016—Agena Bioscience announced the planned commercial launch of its CE-IVD marked MassArray Dx Plus assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics.
January 2016—BioMérieux and Illumina announced the launch of BioMérieux EpiSeq, a next-generation sequencing service dedicated to the epidemiological monitoring and control of health care–associated infections. The EpiSeq service is the first result of the collaboration agreement signed by the two companies in November 2014.
December 2015—Luminex received FDA clearance for its Aries System and Aries HSV 1&2 Assay. Aries is a sample-to-answer molecular diagnostics platform designed to increase laboratory efficiency, ensure result accuracy, and fit into a lean laboratory environment.
December 2015—U.S. Arkray has been awarded a three-year agreement for automated urinalysis with Novation.
December 2015—InSphero has launched a 14-Day Hepatotoxicity Testing Service designed to meet increased demand for contract screening in its patent-pending 3D InSight Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s 3-D liver microtissues by initiating regular screening runs on the first Tuesday of each month, at $990 per compound.
Mopec introduced the Mopec MB800 touchscreen grossing station. Its interactive touchscreen display, which highlights essential grossing station operational information, monitors formalin level, bio waste level, filter usage duration, and ventilation performance. The high-output, touch-free LED lighting system permits adjustments in color and intensity and uniformly illuminates the dissection space, which offers interchangeable grid plates and cutting board surface options.
December 2015—American Medical Technologists announced the approval of the AMT Medical Technologist (MT) exam by the California Department of Public Health, Laboratory Field Services.
December 2015—Luminex received CE-IVD marking for its NxTAG Respiratory Pathogen Panel. The panel detects 21 clinically relevant viral and bacterial respiratory pathogens, including the atypical bacteria Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila.
